Are there new relevant therapeutic endpoints in the modern era of the BCR::ABL1 tyrosine kinase inhibitors in chronic myeloid leukemia?

Hagop M. Kantarjian, Susan Branford, Massimo Breccia, Jörge E. Cortes, Fadi Haddad, Andreas Hochhaus, Timothy P. Hughes, Ghayas C. Issa, Elias Jabbour, Franck E. Nicolini, Koji Sasaki, Francois Xavier-Mahon